Table 1. Demographic and baseline characteristics of the cohort on the basis of achieved on-treatment blood pressure control.
| Good control (n=1733) | Poor control (n=1268) | P-value | |
|---|---|---|---|
| Sex, male | 872 (50.3) | 636 (50.2) | 0.931 |
| Age, years | 63.2±10.4 | 63.4±11.0 | 0.574 |
| BMI, kg m−2 | 24.4±3.4 | 24.7±3.4 | 0.042 |
| Systolic BP, mm Hg | 151.4±10.2 | 157.3±12.4 | <0.001 |
| Diastolic BP, mm Hg | 88.1±9.3 | 89.4±10.2 | <0.001 |
| Heart rate, beat per min | 74.0±11.0 | 74.4±11.5 | 0.320 |
| Previous CV disease | 207 (11.9) | 168 (13.2) | 0.286 |
| Diabetes | 204 (11.8) | 223 (17.6) | <0.001 |
| Dyslipidemia | 702 (40.5) | 515 (40.6) | 0.953 |
| Current smoking | 688 (39.7) | 486 (38.3) | 0.447 |
| Anti-hypertensive agents | 1362 (78.6) | 1061 (83.7) | <0.001 |
| Benidipine | 1076 (62.1) | 835 (65.9) | 0.034 |
| Other CCB | 183 (10.6) | 161 (12.7) | 0.069 |
| ARB | 142 (8.2) | 143 (11.3) | 0.004 |
| ACE inhibitor | 36 (2.1) | 17 (1.3) | 0.130 |
| BB | 56 (3.2) | 36 (2.8) | 0.538 |
| Diuretics | 13 (0.8) | 18 (1.4) | 0.073 |
| α-Blocker | 11 (0.6) | 6 (0.5) | 0.560 |
| Concomitant medication | |||
| Anti-platelets | 138 (8.0) | 103 (8.1) | 0.873 |
| Lipid-lowering agents | 378 (21.8) | 261 (20.6) | 0.417 |
| Statin | 303 (17.5) | 203 (16.0) | 0.287 |
| Antidiabetic agents | 97 (5.6) | 115 (9.1) | <0.001 |
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BB, β-blocker; BMI, body mass index; BP, blood pressure; CCB, calcium channel blocker; CV, cardiovascular.
Data are shown as the number of patients (%) or mean±s.d. Differences in the proportions between the good and poor control groups were analyzed using the χ2-test or unpaired t-test.